Stock Details
GSK is GlaxoSmithKline plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 39.88$. Average daily volumn in 3 months 4.25M. Market cap 99.43B



Stock symbol : GSK. Exchange : NYSE. Currency : USD
Lastest price : 39.52$. Total volume : 4.14M. Market state PRE
Click reload if you want to check the lastest price on market!!!

GlaxoSmithKline plc (GSK)
Last Price
39.52$
Change
0.50
Volume
4.14M

Previous Close39.02
Open39.18
Day Range39.00-39.57
Bid0.00 x 3.1k
Ask0.00 x 800
Volume4.14M
Average Volume4.25M
Market Cap99.43B
Beta0.40
52 Week Range33.26-42.40
Trailing P/E13.78
Foward P/E12.79
Dividend (Yield %)5.57%
Ex-Dividend Date2021-05-20



Financial Details


According to GlaxoSmithKline plc's financial reports the company's revenue in 2020 were 34.1B an increase( +3.03%) over the years 2019 revenue that were of 33.75B. In 2020 the company's total earnings were 5.75B while total earnings in 2019 were 4.64B( +25%).


Loading ...



Organization

GlaxoSmithKline plc is a British multinational pharmaceutical company headquartered in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co. GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck, and Sanofi.

GlaxoSmithKline plc_logo

Market Cap:
99.43B
Revenue:
34.1B
Total Assets:
80.43B
Total Cash:
6.29B


News about "GlaxoSmithKline plc"

GlaxoSmithKline plc (GSK) Reveals an Earnings Mystery_image

GlaxoSmithKline plc (GSK) Reveals an Earnings Mystery

GlaxoSmithKline plc (NYSE:GSK) went up by 1.28% from its latest closing price compared to the recent 1-year high of $42.40. The company’s stock price has collected 1.10% of gains in the last five ...

Source from : newsheater - 9 hours ago


Here’s Our Rant About GlaxoSmithKline plc (GSK)_image

Here’s Our Rant About GlaxoSmithKline plc (GSK)

GlaxoSmithKline plc (NYSE:GSK) went up by 0.40% from its latest closing price compared to the recent 1-year high of $42.40. The company’s stock price has collected 1.17% of gains in the last five ...

Source from : newsheater - 14 days ago


TOP NEWS: GSK retains guidance despite weaker interim results

GlaxoSmithKline PLC on Wednesday held its expectations for 2021 as a whole, in spite of a weaker performance for the first half of the year on lower demand and sales. Shares in Brentford, ...

Source from : London South East - 7 hours ago


GSK, Vir In Deal With EU To Supply 220K Doses Of COVID-19 Treatment Sotrovimab_image

GSK, Vir In Deal With EU To Supply 220K Doses Of COVID-19 Treatment Sotrovimab

Drug major GlaxoSmithKline plc (GSK, GSK.L) and Vir Biotechnology, Inc. (VIR) announced Wednesday that they have signed a Joint Procurement Agreement with the European Commission to supply up to ...

Source from : Nasdaq - 8 hours ago


why GlaxoSmithKline plc [GSK] is a Good Choice for Investors After New Price Target of $49.17_image

why GlaxoSmithKline plc [GSK] is a Good Choice for Investors After New Price Target of $49.17

GSK] closed the trading session at $39.32 on 07/21/21. The day’s price range saw the stock hit a low of $39.10, while the highest price level was $39.40. The company report on July 2, 2021 that Alecto ...

Source from : dbtnews - 6 days ago


BRIEF-GSK Sees 2021 Adj EPS To Decline By Mid-To-High Single-Digit Percentage

RESULTS * Q2 EARNINGS PER SHARE FELL 39 PERCENT TO 27.9 PENCE * GSK SAYS CONTINUES TO EXPECT DIVIDEND OF 80P/SHARE FOR 2021 * Q2 SALES ROSE 6 PERCENT TO 8.1 BILLION ...

Source from : Reuters on MSN.com - 7 hours ago


GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab_image

GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab

GlaxoSmithKline plc (LSE/NYSE: GSK) and (Nasdaq: VIR) today announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an inves ...

Source from : YAHOO!Finance - 8 hours ago


FTSE 100 back above 7000 as airlines climb and GlaxoSmithKline beats forecasts_image

FTSE 100 back above 7000 as airlines climb and GlaxoSmithKline beats forecasts

FTSE 100 adds12 points; Barclays bounces; ITV brighter after results; 12.14pm: Pharma group beats forecasts. GlaxoSmithKline PLC shares are moving higher after the pharmaceuticals ...

Source from : Proactive Investors - 7 hours ago


Why is GlaxoSmithKline plc (GSK) up 1.15% from the day 1 this year?_image

Why is GlaxoSmithKline plc (GSK) up 1.15% from the day 1 this year?

At the end of the latest market close, GlaxoSmithKline plc (GSK) was valued at $40.37. In that particular session, Stock kicked-off at the price of $40.32 while reaching the peak value of $40.59 and ...

Source from : investchronicle - 14 days ago


FTSE 100 above 7000 as GlaxoSmithKline beats forecasts, while Wall Street set for mixed open_image

FTSE 100 above 7000 as GlaxoSmithKline beats forecasts, while Wall Street set for mixed open

FTSE 100 adds 15 points; Dow expected to open slightly lower; Barclays bounces after results; 12.32pm: US investors uncertain ahead of Fed. Wall Street looks like it is playing th ...

Source from : Proactive Investors - 7 hours ago


Shares Of GlaxoSmithKline plc (NYSE: GSK): Are They Overvalued Compared To Others?

GlaxoSmithKline plc (NYSE:GSK) shares, rose in value on Thursday, July 22, with the stock price down by -0.23% to the previous day’s close as strong demand from buyers drove the stock to $39.23.

Source from : stocksregister - 5 days ago


Shares Of GlaxoSmithKline plc (NYSE: GSK) Loss -0.85% In A Month

GlaxoSmithKline plc (NYSE:GSK) has a beta value of 0.69 and has seen 3.75 million shares traded in the last trading session. The company, currently valued at $97.24B, closed the last trade at $39.51 ...

Source from : marketingsentinel - 2 days ago


GlaxoSmithKline, Vir Biotechnology to Supply Covid-19 Treatment to European Commission

By Chris Wack GlaxoSmithKline PLC and Vir Biotechnology Inc. said they have signed a joint procurement agreement with the European Commission to supply up ...

Source from : MarketWatch - 7 hours ago


GlaxoSmithKline 2Q Net Profit Drops Despite Higher Sales; Backs 2021 Outlook

GlaxoSmithKline PLC said Wednesday that net profit dropped in the second quarter compared with the previous year, though sales grew on-year and it backed its outlook for the full year. The British ...

Source from : Morningstar, Inc. - 12 hours ago


BRIEF-GSK And Vir Biotechnology Announce Joint Procurement Deal With European Commission For Sotrovimab

GSK AND VIR BIOTECHNOLOGY ANNOUNCE JOINT PROCUREMENT AGREEMENT WITH EUROPEAN COMMISSION FOR COVID-19 TREATMENT, SOTROVIMAB * GSK - AGREEMENT WITH THE EUROPEAN COMMISSION TO SUPPLY UP TO 220,000 DOSE ...

Source from : Reuters on MSN.com - 8 hours ago


GlaxoSmithKline PLC : Board Committee Changes

Disclaimer | Accessibility Statement | Commerce Policy | Made In NYC | Stock quotes by finanzen.net SHARE THIS POST GlaxoSmithKline NewsMORE Related Stocks Find News News ...

Source from : Business Insider - 5 days ago


GlaxoSmithKline PLC : Director/PDMR Shareholding

Disclaimer | Accessibility Statement | Commerce Policy | Made In NYC | Stock quotes by finanzen.net SHARE THIS POST GlaxoSmithKline NewsMORE Related Stocks Find News ...

Source from : Business Insider - 12 days ago


GlaxoSmithKline : FDA Approves Shingrix To Prevent Shingles In Immunocompromised Adults

The US Food and Drug Administration has approved Shingrix--Zoster Vaccine Recombinant, Adjuvanted-- for the prevention of shingles in adults aged 18 years and older who are or who will be at increased ...

Source from : Nasdaq - 2 days ago


Yellow Fever Market to Explore Excellent Growth in Future : Pfizer, Glaxosmithkline, Merck_image

Yellow Fever Market to Explore Excellent Growth in Future : Pfizer, Glaxosmithkline, Merck

The Global Yellow Fever Market outlook survey highlights the dynamics at play in each of the subsegments of Yellow Fever Industry to better elaborate current state, emerging trends and potential areas ...

Source from : SBWire - 1 days ago


Insights on the Respiratory Inhalers Global Market to 2027 - Featuring AstraZeneca, Cipla and GlaxoSmithKline Among Others - ResearchAndMarkets.com

The "Respiratory Inhalers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Source from : YAHOO!Finance - 9 hours ago


Pipeline, Vaccines in Focus for GlaxoSmithKline as 2Q Profit Expected to Drop -- Earnings Preview

By Cecilia Butini GlaxoSmithKline PLC is scheduled to report results for the second quarter on Wednesday. Here's what you need to know: SALES FORECAST: ...

Source from : MarketWatch - 2 days ago


GlaxoSmithKline plc (NYSE: GSK) Stock Forecast: By 2021, Bulls Expect $53.26 Per Share

In the last trading session, 6.3 million shares of the GlaxoSmithKline plc (NYSE:GSK) were traded, and its beta was 0.69. Most recently the company’s share price was $39.09, and it changed around -$0.

Source from : marketingsentinel - 7 days ago


GlaxoSmithKline plc (GSK) is on the roll with an average volume of 4.22M in the recent 3 months

For the readers interested in the stock health of GlaxoSmithKline plc (GSK). It is currently valued at $39.12. When the transactions were called off in the previous session, Stock hit the highs of $39 ...

Source from : investchronicle - 7 days ago


GlaxoSmithKline plc’s (NYSE: GSK) Stock Price Continues To Fall

The trading price of GlaxoSmithKline plc (NYSE:GSK) floating lower at last check on Monday, July 19, closing at $39.17, -0.34% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Econo ...

Source from : stocksregister - 8 days ago


Global Inflammatory Pain Market Foraying into Emerging Economies| Advacare Pharma, Glaxosmithkline Plc (GSK),

The global Inflammatory Pain Market has the potential to grow by USD xx during 2021-2027, and the market’s growth momentum will accelerate throughout the forecast period. This report provides a ...

Source from : manometcurrent.com - 5 days ago


GSK ‘encouraged’ by Covid vaccine rollout as sales and profits jump_image

GSK ‘encouraged’ by Covid vaccine rollout as sales and profits jump

GSK said it had anticipated some disruption in its vaccine business as the Government prioritised Covid-19 vaccinations, but the firm said it has been “encouraged” by the rate ...

Source from : Express & Star - 7 hours ago


Massive Growth of Consumer Healthcare Products Market by 2027 | Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxosmithKline plc_image

Massive Growth of Consumer Healthcare Products Market by 2027 | Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxosmithKline plc

Consumer Healthcare Products Market from the perspective of all its current trends that are influencing it is important to understand in order to obtain the most rounded solution for business ...

Source from : manometcurrent.com - 13 days ago


GlaxoSmithKline PLC - GSK and Alector collaboration in immuno-neurology

Parkinson's disease and Alzheimer's disease GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation ...

Source from : Proactiveinvestors - 26 days ago


Bonness Enterprises Inc Buys GlaxoSmithKline PLC, AT&T Inc

Washington, DC, based Investment company Bonness Enterprises Inc (Current Portfolio) buys GlaxoSmithKline PLC, AT&T Inc during the 3-months ended 2021Q2, according to the most recent filings of the ...

Source from : Yahoo Finance - 15 days ago


GSK, Alector to develop Parkinson's, Alzheimer's drugs in $2.2 bln deal

July 2 (Reuters) - GlaxoSmithKline Plc (GSK.L) and U.S. firm Alector Inc (ALEC.O) will together develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases in a deal ...

Source from : Reuters - 26 days ago


Elliott Calls for Board Changes at GlaxoSmithKline Ahead of Consumer-Healthcare Spinoff — Update

Activist investor Elliott Management Corp. has called on GlaxoSmithKline PLC to assess its board and management ahead of a long-planned separation of its consumer-healthcare business, and to ...

Source from : Morningstar%2c Inc. - 27 days ago


GSK, Alector to develop Parkinson’s and Alzheimer’s drugs in $2.2 billion deal

(Reuters) – GlaxoSmithKline Plc (GSK.L) and U.S. firm Alector Inc (ALEC.O) will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to ...

Source from : PharmaLive - 26 days ago


UPDATE: Glaxo joins Alector on brain treatment trials; backs leader

(Alliance News) - GlaxoSmithKline PLC on Friday said it has partnered with Alector Inc to develop brain disease treatments, as it defends its leadership in response to a scathing open letter from ...

Source from : London South East - 26 days ago


GSK, Alector to develop Parkinson's, Alzheimer's drugs in $2.2 billion deal

(Reuters) - GlaxoSmithKline Plc and U.S. firm Alector Inc will together develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases in a deal worth up to $2.2 billion, ...

Source from : Yahoo News - 26 days ago


Activist Investor Calls for Leadership Shake-Up at GSK

The shares of GlaxoSmithKline plc (NYSE:GSK) are up 0.4% at $39.96 this morning, following news that Elliott Management has urged the British pharmaceutical company to name a new set of board ...

Source from : SchaeffersResearch.com - 27 days ago


GSK, Alector to develop Parkinson's, Alzheimer's drugs in $2.2 bln deal

July 2 (Reuters) - GlaxoSmithKline Plc and U.S. firm Alector Inc will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 ...

Source from : Reuters - 23 days ago


10 Best Psychedelic Companies to Watch

In this article, we discuss the 10 best psychedelic companies to watch. If you want to skip our detailed analysis of these companies, go directly to the 5 Best Psychedelic Companies to Watch.

Source from : Insider Monkey - 28 days ago


Sanofi, GSK get Indian approval for late-stage trial of COVID-19 vaccine

(Reuters) - Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said ...

Source from : Yahoo News - 20 days ago


The Curious Case Of Elliott Advisors And GSK: Are Activist Investors What They Used To Be?

Emma Walmsley, chief executive officer of Glaxosmithkline Plc, poses for a photograph following a ... [+] Bloomberg Television interview at the Glaxo headquarters in the Brentford district of ...

Source from : Forbes - 18 days ago


GlaxoSmithKline taps Goldman, Citi to advise on consumer unit spinoff - Bloomberg News

June 25 (Reuters) - GlaxoSmithKline Plc has hired two banks to help advise it on listing its consumer unit next year and on defense against a potential activist campaign from Elliott Investment ...

Source from : Reuters - 1 month ago


Sanofi, GSK get Indian approval for late-stage trial of COVID-19 vaccine

(Reuters) – Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers ...

Source from : Metro US - 20 days ago


Nvidia gives health researchers access to UK supercomputer

Nvidia Corp on Wednesday said it opened what it claims is the fastest UK supercomputer to outside researchers that include both academic scientists and commercial firms such as AstraZeneca PLC and ...

Source from : Channel NewsAsia Singapore - 21 days ago


Activist investor Elliott pushes shake-up at GlaxoSmithKline

Activist investor Elliott Management Corp. has intensified pressure on GlaxoSmithKline PLC, calling on the pharmaceutical giant to replace members of its board and launch a process to decide ...

Source from : Mint - 27 days ago


Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial

Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.

Source from : NDTV - 20 days ago


GlaxoSmithKline Says Board Supports Under-Pressure CEO

GlaxoSmithKline PLC said its board sees Chief Executive Emma Walmsley as the right person to lead the company’s pharmaceutical business after a planned split with its consumer-health unit ...

Source from : Wall Street Journal - 26 days ago


Sanofi SA and GlaxoSmithKline Plc get nod for trial of jab

India’s top drug regulator has given go ahead to Sanofi SA and GlaxoSmithKline Plc for a late-stage clinical trial of their protein-based Covid-19 vaccine candidate, the drugmakers said on Thursday.

Source from : The Pioneer - 19 days ago


GSK, Alector to develop Parkinson’s, Alzheimer’s drugs in $2.2 billion deal

(Reuters) – GlaxoSmithKline Plc and U.S. firm Alector Inc will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 ...

Source from : Metro US - 26 days ago


Sanofi, GSK get India’s approval for late-stage trial of Covid-19 vaccine

NEW DELHI: Sanofi SA and GlaxoSmithKline Plc have received approval from Indian authorities for a late-stage clinical trial of their protein-based Covid-19 vaccine candidate, the drugmakers said ...

Source from : Free Malaysia Today - 20 days ago